{"schema_version":"secwatch.filing_event.v1","accession":"0001420720-24-000053","form_type":"8-K","ticker":"IBIO","cik":"0001420720","company_name":"iBio, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.408044+00:00","generated_at":"2026-05-30T01:42:48.398140+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"iBio Q1 fiscal 2025: net loss $4.0M ($0.46/sh), no revenue; advancing myostatin NHP study","bullets":["No revenue for quarter ended Sep 30, 2024; net loss from continuing ops $4.0M ($0.46/sh) vs $5.1M ($4.24/sh) YoY.","R&D and G&A expenses decreased ~20% YoY to $4.1M as part of cash preservation strategy.","Cash, equivalents, and restricted cash $11.3M at Sep 30, 2024 (incl $0.2M restricted).","Collaboration with AstralBio: lead molecule for muscle wasting/obesity dosed in NHP study; early readouts expected early 2025.","Appointed Kristi Sarno as SVP of Business Development effective Aug 1, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001420720-24-000053","json":"https://secwatch.observer/filing/0001420720-24-000053.json","markdown":"https://secwatch.observer/filing/0001420720-24-000053.md","text":"https://secwatch.observer/filing/0001420720-24-000053.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420720/000142072024000053/0001420720-24-000053-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420720/000142072024000053/ibio-20240930x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:42:48.398140+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}